All News
As the BA.4/BA.5 Omicron subvariants spread, researchers continue to develop COVID-19 therapies and approaches for preventing or treating the disease. For that and more, continue reading.
Cancer research facilities are leading the way with methods that will lead to better detection of cancer metastasis, better understanding of cancer cell physiology and greater patient response.
The Bay State, home to the busy bio-hub Genetown, is experiencing some growing pains. Companies like Biogen and Eisai (H3 Biomedicine) are reducing their headcount.
Innovent Biologics’ Phase II trial of mazdutide, a potential treatment for type 2 diabetes, showed the drug met its primary endpoint by successfully reducing HbA1c levels.
The FDA has approved Incyte’s Opzelura as the first and only at-home therapy for repigmentation in nonsegmental vitiligo.
The buyout comes on the heels of promising Phase I/II results from GTX-102, an antisense oligonucleotide candidate being developed to treat Angelman syndrome.
There are myriad misconceptions about prescription stimulants for ADHD. But buried within the array of opinions, as with many hot-button topics, are small nuggets of truth.
Five weeks after taking the reins as CEO of CRISPR-focused Editas Medicine, Gilmore O’Neill fulfilled his first task, appointing a new chief medical officer.
NASA and Cedars-Sinai Medical Center have sent stem cells into space in order to determine whether they grow differently without G-force.
In what it is calling a strategic decision, Sesen Bio announced Monday that it has paused development activities of Vicineum, its lead asset, in the United States.
The delay is due, in part, to some internal Seagen actions, including a data readout for its bladder cancer drug Padcev, as well as a legal matter between Seagen and Daiichi Sankyo.
GSK, whose shares were up about 3.3% Monday, will likely use part of the 7 billion pounds it will generate via the Haleon spinoff to make acquisitions.
This type of Y chromosome loss is called mLOY (mosaic Loss Of Y). Mosaic refers to a mix of chromosomally different cells, with some being 46,XY and others being 45,X,-Y.
From the initial interview to the annual raise, discussions about salary are vital in every work environment. Find out how implementing salary transparency can help you find and keep top talent.
In the latest in Nestlé’s efforts to establish a presence in the gastroenterology space, the company will pay over $40 million upfront to Enterome as part of a new partnership.
To learn how women and underrepresented groups can secure seats on boards of directors, BioSpace spoke with perception analyst Dian Griesel and board member Terry Coelho.
Mid-July is a relatively quiet time for the FDA in terms of drug approvals, but Incyte and Arcutis will have all eyes on the regulator as they await decisions in vitiligo and psoriasis.
MacroGenics’ Phase II trial shuts down after a patient death believed to be related to enoblituzumab combo, while Exelixis’ Cabometyx combo improves PFS in renal cell carcinoma.
Roche had a good week, sharing positive data from Genentech’s study on Vabysmo for age-related macular degeneration and its breast cancer combination therapy, Perjeta.
Discover the biggest barriers patients face when seeking healthcare treatment, and find out what physicians can do to help patients overcome these barriers and improve patient engagement.